Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry CD20 Test

The Immunohistochemistry CD20 Test detects the CD20 protein in tumor tissue, aiding in the diagnosis and treatment planning for certain B-cell cancers like lymphomas. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Confirm with the laboratory before booking. Typically 5 days for standard tissue biopsy and 7 days for large complex tissues.
Preparation
No specific patient preparation is required. Ensure the submitted tissue is properly labeled with patient information, site of biopsy, and date. A copy of the Histopathology report and relevant clinical history should accompany the sample.
Test priceKSh 6,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry CD20 Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of suspected B-cell lymphomas
  • ✓Classification of lymphoma subtypes
  • ✓Guiding treatment decisions for B-cell malignancies
  • ✓Monitoring response to CD20-targeted therapy
  • ✓Evaluating patients with unexplained lymphadenopathy
  • ✓Investigating suspected B-cell related cancers
02

In plain language

What this test helps you understand

Aids in the diagnosis and classification of B-cell malignancies, particularly lymphomas. Helps guide treatment decisions, including the use of targeted therapies like Rituximab. Assists in monitoring disease progression and response to treatment.
The Immunohistochemistry CD20 Test is a specialized diagnostic procedure used to evaluate certain types of cancers, particularly lymphomas. This test identifies the presence of the CD20 protein on the surface of B-cells. This information is crucial for oncologists in determining the appropriate treatment and management strategies for cancer patients.

This test specifically measures the expression of CD20, a protein found on B-lymphocytes. Detecting CD20 is significant in diagnosing and classifying B-cell malignancies, including various forms of non-Hodgkin lymphoma.

This test is recommended for individuals experiencing symptoms potentially related to B-cell malignancies, such as unexplained weight loss, persistent fever, night sweats, swollen lymph nodes, or significant fatigue. Patients with a known history of B-cell cancers or those with a family history may also be advised to consider this test.

Benefits of this test include aiding in the accurate diagnosis of B-cell malignancies, guiding treatment decisions (including targeted therapies), monitoring disease progression, and helping oncologists tailor patient management plans.

Results indicate whether CD20 is present in the tumor tissue. A positive result may suggest the cancer might respond to CD20-targeted therapies. Discuss your results thoroughly with your oncologist to understand their implications and next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. Ensure the submitted tissue is properly labeled with patient information, site of biopsy, and date. A copy of the Histopathology report and relevant clinical history should accompany the sample.
SampleTumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) using specific antibodies against the CD20 protein.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects the presence or absence of CD20 protein. It does not provide information about the overall prognosis or predict response to all therapies. Results must be interpreted in the context of clinical findings and other diagnostic tests. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

CD20 is a protein found on the surface of B-lymphocytes (a type of white blood cell). It is often used as a marker for B-cell cancers.
Detecting CD20 helps identify and classify certain types of cancer, particularly B-cell lymphomas, and can guide treatment decisions.
A sample of tumor tissue, typically from a biopsy, is required. It should be formalin-fixed and paraffin-embedded or in formalin-saline.
Turnaround time can vary. Confirm with the laboratory before booking. Standard results may be available within 5 days, while complex samples may take up to 7 days.
A positive result indicates the presence of CD20 on the tumor cells. Your doctor will interpret this result along with other clinical information to determine the best course of action.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp